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Abstract
Background: Chronic disease accounts for nearly three-quarters of US deaths, yet prevalence rates are not
consistently reported at the state level and are not available at the sub-state level. This makes it difficult to assess
trends in prevalence and impossible to measure sub-state differences. Such county-level differences could inform
and direct the delivery of health services to those with the greatest need.
Methods: We used a database of prescription drugs filled in the US as a proxy for nationwide, county-level
prevalence of three top causes of death: heart disease, stroke, and diabetes. We tested whether prescription data
are statistically valid proxy measures for prevalence, using the correlation between prescriptions filled at the state
level and comparable Behavioral Risk Factor Surveillance System (BRFSS) data. We further tested for statistically
significant national geographic patterns.
Results: Fourteen correlations were tested for years in which the BRFSS questions were asked (1999-2003), and all
were statistically significant. The correlations at the state level ranged from a low of 0.41 (stroke, 1999) to a high of
0.73 (heart disease, 2003). We also mapped self-reported chronic illnesses along with prescription rates associated
with those illnesses.
Conclusions: County prescription drug rates were shown to be valid measures of sub-state estimates of diagnosed
prevalence and could be used to target health resources to counties in need. This methodology could be
particularly helpful to rural areas whose prevalence rates cannot be estimated using national surveys. While there
are no spatial statistically significant patterns nationally, there are significant variations within states that suggest
unmet health needs.
Background
Chronic diseases exact a toll on the population, yet most
national surveillance systems addressing the level of pre-
valence lack the geographic detail necessary to allow pub-
lic health officials to intervene effectively in terms of
health services allocation, especially in rural areas. Health
officials must depend on data from the National Health
Interview Survey (NHIS), the National Health and Nutri-
tion Examination Survey (NHANES), and the Behavioral
Risk Factors Surveillance System (BRFSS) to calculate the
nationwide prevalence of chronic illnesses [1], although
the limitations of these surveys for measuring minority
populations are well-known [2,3]. Due to the nature of
survey design, statistics cannot be derived for rural areas,
although data for selected metropolitan areas have been
made available [4]. Given survey data limitations, the
population of nearly two-thirds of US counties is
excluded from the sample population. Shifting disease
surveillance to the county level with county data has the
potential to create a surveillance system that more accu-
rately characterizes the public health burden of chronic
illnesses, identifies high-concentration areas, improves
health care resource targeting, and advances disease pre-
vention and control at a localized level.
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The achievement of national health goals is directly
tied to the ability to target intervention strategies to
people residing in specific geographic areas [5]. The
higher the data resolution, the more effectively resources
could be allocated. Most adults diagnosed with heart
disease, high blood pressure, and diabetes report taking
prescription medication for their illnesses (heart disease
– 81% in 1987 and 77% in 2001; high blood pressure –
94% in 1987 and 97% in 2001 [6]; diabetes – 83% in
1987 and 93% in 2001 [6], 85% in 2001 [7] or 83% in
2001-2002 [8], depending on the survey). Reliable pre-
scription data at the sub-national level could be a valid
proxy measure for the prevalence of these chronic ill-
nesses. We tested the viability of using data on prescrip-
tions filled as a proxy measure for illness prevalence
rates by comparing prescriptions-filled rates with state-
level BRFSS data, using population estimates to supple-
ment survey estimates.
As a point of clarification, cancer, the second-leading
cause of death in the US, was not one of the selected
chronic conditions in the prescriptions-filled dataset.
Most cancer drugs are used in hospitals, clinics, and
physician offices and thus would not reflect the resi-
dence of individuals with cancer, a central feature of
this research.
The Dartmouth Atlas of Health Care in the United
States is the most comprehensive study of smaller area
geographic variation in diseases, but it was carried out
at the level of Hospital Service Area and Hospital Refer-
ral Regions [9-11]. A study similar to the Dartmouth
Atlas examined prescription drug use in Michigan but
did not address major chronic disease prescription med-
ications in particular [12]. Despite significant regional
variations found in a study of Medicare data for a group
of male Hispanics experiencing renal failure, data con-
straints mean that geography typically gets introduced
into research models only as a consideration for rural
versus urban populations [13]. Even the rural-urban dis-
tinction yields important insights for medically under-
served populations. Rural African Americans are less
likely to control their diabetes and hypertension than
their urban counterparts, and American Indians have
significant regional variations in risk and prevalence of
diabetes [14-16]. Recognizing spatial differences in dia-
betes treatment, the National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK) is funding
research on regional variations in health outcomes
among diabetic minorities [17], and the Agency for
Healthcare Research and Quality is funding research on
geographic patterns in recurrent strokes [18].
Some state-specific studies have been produced,
although they differ from the depth of analysis that we
propose. For example, the Prescription Drug Atlas [19]
describes the geographic distribution of a number of
drug classes, based on a convenience sample of Express
Script plan customers. The Centers for Disease Control
and Prevention (CDC) results from the 1988 and 1989
BRFSS revealed the predominance of states with high
diabetes rates grouped east of the Mississippi River, with
none of the highest-rate states in the West [20,21].
More recently, CDC researchers decomposed the BRFSS
to 100 metropolitan statistical areas (MSA) to examine
the prevalence of Type 2 diabetes [22]. Researchers
from the State Center for Health Statistics in North
Carolina used results from their 10 most populous
counties and then aggregated the remaining 90 counties
into three regions [23]. A recent review of the Indicators
for Chronic Disease Surveillance noted that the current
system is restricted to state and national levels of geo-
graphy for surveillance, confirming this lack of county-
level specificity [24].
Our population-level methodology overcomes some
problems found in state-level studies. As Geiss et al
noted, “Data from population-based studies are generally
considered more reliable than data from selected groups
within the population because the latter may not repre-
sent the community with respect to factors such as age
and health status” [25]. The full dimensions of the rela-
tionship between diagnosis and prescription drug treat-
ment are unknown, but a significant proportion of the
diagnosed population can be identified via prescription
drug use.
We mapped chronic illness prevalence at a finer geo-
graphic scale than MSA or hospital region using pre-
scription data. Statistical analysis using health data
mapping enables social and medical scientists to more
accurately identify and display areas with high and low
disease prevalence rates. This methodology cuts across
nominal data categories to potentially reveal cross-sec-
tional and longitudinal geographic patterns and clusters
that are otherwise masked. Spatially based chronic dis-
ease prevalence data could also be used to address the
critical issue of racial and ethnic disparities in health
and health care at the county level [26,27].
Methods
We used one dataset to select the prescription drugs of
interest, a different dataset of prescriptions filled at the
county level as a proxy measure for chronic diseases, a
third dataset to perform an age truncation with a
national medical care survey, and a final dataset to cal-
culate correlations as a means of validating the prescrip-
tion data measure.
IMS Health, Inc., collected prescription drug data
from nearly 30,000 suppliers covering 225,000 sites (e.g.,
drug manufacturers, wholesalers, retailers, pharmacies,
mail order, long-term care facilities, and hospitals). A
fuller description of IMS Health’s products was
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previously published [28]. To determine the prescription
drug classes appropriate for major chronic diseases, we
used IMS Health’s National Disease and Therapeutic
Index (NDTI), a database derived from an ongoing
office-based physician panel providing national-level
estimates of disease and treatment patterns for office-
based physicians. (We chose not to use an expert phar-
macy panel to avoid training or practice bias.) The data
in NDTI captured all medications associated with a
patient visit for a particular treatment. The leading ther-
apeutic classes (also known as Uniform System of Clas-
sification or USC) used for the three diseases were
identified from this dataset.
The USC classes chosen for diabetes were: (USC
39211) Sulfonylureas, (USC 39220) Biguanides, and
(USC 39230) Insulin sensitizers. (Specifically, the drug
types included: animal insulins, human insulins, human
insulin analogues, sulfonylureas, meglitinides, amino
acid derivatives, biguanides, insulin sensitizers, alpha-
glucosidase inhibitors, diabetes therapy combinations,
and diabetic accessories.)
The classes chosen for heart disease were: (USC
31100) Renin Angiotensin Systemic Antagonist, (USC
31400) Beta and Alpha blockers, and (USC 32000) Cho-
lesterol reducers and Lipotropics. (Specifically, these
included Angiotensin-Converting Enzyme (ACE) inhibi-
tors (along with diuretics and other), angiotensin II type
I receptor antagonist (alone and in combination), per-
ipheral vasodilators, calcium blockers, beta blockers,
alpha-blockers, beta/alpha blockers (with diuretics),
alpha blockers (alone and in combination), central act-
ing agent (alone and in combination), antihypertensive
(other), HMG-COA reductase inhibitor (3-hydroxy-
3methylgluatryl coenzyme A reductase), bile acid
sequestrants, fibric acid derivative, cholesterol absorp-
tion inhibitor, cholesterol red combination, lipotropics,
and antihyperlipidemic agent (other).
The classes chosen for cerebrovascular disease were:
(USC 11110) Anticoagulants, (USC 11200) Antiplatelets,
and (USC 20200) Seizure disorders. (Specifically, the
drug types included: anticoagulant (oral), unfractionated
heparins, fractionated heparins, heparines for flushing,
injected anticoagulants (other), antiplatelets (oral and
injected), fibrinolytic, Vitamin K & related (oral and
injected), hemo mod other (injected, oral, topical), l-
dopa, antiparkinson (other), movement disorders
(other), seizure disorders, anti-ALS, Alzheimer-type
dementia, and neurological disorders (other).
Based on the results from the NDTI, we purchased
monthly, county-level prescriptions-filled data for 1999-
2003 for the chosen drug classes in IMS Health’s Xpo-
nent database. Total US prescription sales were deter-
mined from IMS Health’s independently sourced Drug
Distribution Data and obtained from pharmaceutical
manufacturers, drug wholesalers, and chain warehouses,
reported at the individual outlet level. This count
included 72% of all prescriptions filled at the individual
retail level (February 2006), a stable rate since 1998 to
the present. To estimate the remaining 28%, IMS
weights retail data to generate estimates representing
total dispensed prescription volume at the national, sub-
national, and prescriber level. IMS used volume data
and pharmacy distance measures to determine applic-
able weights for sample pharmacies to estimate the dis-
pensed prescription volume for each nonsample
pharmacy. Weights were derived through an IMS Health
proprietary, patented geo-spatial methodology (personal
communication, Stuchlak W: Senior Principal, IMS
Management Consulting, IMS Health, Plymouth Meet-
ing: March 31, 2006; PA).
According to IMS Health, retail pharmacies account
for 67% of total national prescription sales for therapeu-
tic categories used in the treatment of chronic illnesses.
About 23% of sales occur via mail, 8% occur in clinics,
long-term care, prisons, universities, and nonfederal hos-
pitals, and 2% occur within federal facilities (e.g., Veter-
ans Administration) [29].
The prescription dataset does not contain patient
demographics. To place the prescription data on an
equal footing with the BRFSS, which surveys only adults,
we determined the percentage of those under 18 who
receive diabetes medications (the medication most likely
among the three to be taken by children). We used the
National Ambulatory Medical Care Survey (NAMCS), a
national probability sample survey of visits to office-
based physicians conducted by the National Center for
Health Statistics [30]. In addition to patient demo-
graphics, NAMCS collects data on the therapeutic class
of drug prescribed. We aggregated 2000-2002 files to
Census-regions level. The denominator, age 18+ state
resident population, was derived from the US Census
Bureau’s inter-censal population estimates. For a full
explanation of the methodology, see “Methodology for
the State and County Total Resident Population Esti-
mates (Vintage 2009): April 1, 2000 to July 1, 2009”
[31]. Among patients under age 20 (the closest age cut-
point), the usage of diabetes medications was always
below 1%, indicating that children could be dropped
from the base population.
A rolling 12-month average was calculated to smooth
the rates and to account for multiple-month prescrip-
tion fills. The refined rate of prescriptions-filled calcula-
tion is:
(Estimated prescriptions by category
filled in a calendar y
   
    ear in the state months
Age and over resident sta
      
     
) / 12
18 te population in s   100( )
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We did not attempt to adjust for the three-month
order because it was not widely available in 1999-2003.
We cannot fully account for those who only fill their
prescriptions for only part of the year beyond our roll-
ing 12-month calculation. As an example, in 2003, pre-
scriptions in the retail channel, which were
overwhelmingly 30-day supplies at the time, accounted
for 86% of all prescriptions for the Angiotensin Receptor
Blocker drug class. Mail order prescriptions, which are
typically for 90 days, only accounted for 10% of ARB
prescriptions, and long-term care accounted for the
remaining 4% of ARB prescriptions.
BRFSS, a state-level monthly telephone survey of
adults about behaviors associated with health risks and
the incidence of medical conditions, provided our
reference point [32]. BRFSS data have been routinely
used to create state-level estimates of chronic illness,
health risks, and national prevalence rates, and more
recently, for metropolitan and micropolitan area preva-
lence rates; however, due to the survey design, the
BRFSS continues to undersample rural residents. We
used the following three survey questions from the
1999-2003 BRFSS: “Have you ever been told by a doc-
tor, nurse or other health professional that you had: (i)
diabetes, (ii) coronary heart disease or (iii) high blood
pressure?”
An important shortcoming of existing survey data is
that they are not spatial in nature. According to Stan
Openshaw, an early leader in exploratory data visualiza-
tion: “People DIE each year because no one BOTHERS
to properly analyze DISEASE and DEATH data for unu-
sual localized concentrations” [[33], emphasis in origi-
nal]. Maps are often used to display health information,
but typically there is an inadequate effort to empirically
identify spatial patterns or apply spatial statistics to test
hypotheses. We mapped and compared state-level
results from BRFSS and IMS data; IMS data were also
mapped at the county level. After visually assessing
maps presented here, we conducted a statistical test of
spatial autocorrelation to test whether prescriptions-
filled rates were equally likely to occur at any location,
using the Global Moran’s I [34].
Results
Introduction
Direct comparisons between the state-level IMS Health
prescription rates and the state-level BRFSS disease pre-
valence rates are restricted by the number of states
reporting to BRFSS in each year. Only the diabetes
question was asked in all states in all five years. We
paired drug classes with appropriate BRFSS questions
(Table 1). The statistically significant correlations ranged
from a low of 0.41 to a high of 0.73 for years in which
all states reported.
The correlation between self-reported diabetes and
diabetes prescriptions was consistently high (Table 1).
The correlation between self-reported high blood pres-
sure and heart disease prescriptions was slightly higher
than the correlation between self-reported high blood
pressure and stroke prescriptions. While the correlation
was high and statistically significant, only a small num-
ber of states have reported. Therefore, these results
should be viewed with caution.
Diabetes
When comparing the state-level IMS Health prescrip-
tion rates with the state-level BRFSS diabetes prevalence
rates, the correlations ranged from 0.59 to 0.71 (p < .01,
Table 1.) We excluded gestational diabetes (<1% of
national cases) as a temporary condition [35]. The
BRFSS mean state-level adult prevalence rate ranged
from 5.6% to 7.1%, while the state-level adult prescrip-
tions-filled rates for diabetes medications were roughly
half that. When the prescription rates were further
Table 1 Correlations of State-level BRFSS to State-level Rx
Disease Question vs. Prescription Matched 1999 2000 2001 2002 2003
BRFSS Q: “Has a doctor, nurse, or other health professional ever told you that you have angina or coronary
heart disease?” vs. Heart disease prescriptions filled
0.438a – 0.662a – 0.613a
N (states) 21 14 20 7 24
BRFSS Q: “Have you ever been told by a doctor, nurse or other health professional that you have high blood
pressure?” vs. Heart disease prescriptions filled
0.537a – 0.635a – 0.733a
N (50 states plus District of Columbia) 51 6 51 11 51
BRFSS Q: “Have you ever been told by a doctor, nurse or other health professional that you have high blood
pressure?” vs. Stroke prescriptions filled
0.406a – 0.499a – 0.622a
N (50 states plus District of Columbia) 51 6 51 11 51
BRFSS Q: “Have you ever been told by a doctor that you have diabetes?” vs. Diabetes prescriptions filled 0.588a 0.609a 0.625a 0.695a 0.713a
N (50 states plus District of Columbia) 51 51 51 51 51
a = Correlation is significant at the 0.01 level (2-tailed test)
– Data unavailable;
Note: Correlations with populations of less than 30 are unstable and should be viewed with caution
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disaggregated to the county level, the average county
rate of diabetes prescriptions filled ranged from 2.2% to
2.7%, although 20% of US counties were in the top
quintile of 4% to 18%. The ratio of the prescriptions-
filled rates to the BRFSS prevalence rates was relatively
stable across time, at 0.6.
Although the two diabetes prevalence rates differ (7%
vs. 4%), they are fundamentally different measures and
were not expected to be equal. In the case of diabetes,
according to the NIDDK, the combined US prevalence
rate for Type 1 and Type 2 diabetes is 7% (in 2003); of
that, 95% was Type 2, which yields a Type 2-only preva-
lence rate to 6.8%. Among these cases, 70% were diag-
nosed, yielding an estimated Type 2 prevalence rate of
4.7%. Among the remaining cases, only 85% were drug-
treated, yielding an estimated Type 2 prevalence rate of
4% [36]. This estimated prevalence percentage was very
close to the level produced by our prescription drug
methodology (4.1% vs. 4.0%)(Table 2). Additionally, a
study similar to ours in Portugal found this prescription
methodology slightly underestimated diabetes prevalence
compared to a national health survey [37]. Double
counting of individuals via the total number of prescrip-
tions filled (e.g., counting two different prescription
drugs as two different individuals) would be unlikely
because almost 90% of individuals in drug therapy are
receiving monotherapies or a single drug treatment [38].
We used quintiles to facilitate comparisons between
relative differences in diabetes prevalence between the
BRFSS and prescriptions-filled maps. The color ramp
was based on the ColorBrewer color diagnostic tool
[39]. Figure 1 displays mapped BRFSS data, with 10
states in each category except for the dark green cate-
gory with 11. The self-reported prevalence rates range
from 4.7% to 11%. This map shows 10 states ranked
“very high” in diabetes prevalence rates (WV, OH, KY,
TN, SC, FL, AL, MS, LA, and DC). The remainder of
the South ranks as an area of “high” prevalence (7.4% -
8.1%). Strikingly, the Midwest and West were generally
“very low” (4.7% - 6%) and “low” (6% - 6.7%). Overall,
BRFSS mapped state-level data suggest diabetes preva-
lence rates were divided into high-prevalence East and
low-prevalence West zones, with a cluster of “very high”
states roughly following the Appalachian mountain
region. The Global Moran’s I for Figure 1 is 0.57, which
indicates a relatively low degree of positive spatial auto-
correlation (ie, the spatial pattern is not random) (p =
0.001). A positive spatial autocorrelation (+0.5 to +1)
indicated neighboring counties were more like each
other than distant counties. Conversely, a negative spa-
tial autocorrelation (-0.5 to -1) indicated the rates in
neighboring counties were unlike each other. Scores of
-0.4 to +0.4 suggest weak autocorrelation, with a score
of 0.0 indicating no spatial autocorrelation at all, a
totally random geographic distribution.
The IMS Health state-level prescription data map
(Figure 2) was generally similar to the BRFSS map.
Though the range for categories was not equal (BRFSS
ranges 4.7% - 11% vs. Rx ranges 2.4% - 6.3%), quintiles
allowed for a map-to-map comparisons of the relative
top 20%, the next highest 20%, etc. The prescriptions-
filled map displayed the same cluster of high rates in
the East, specifically the South, while lower rates were
clustered in the Midwest and West. Since these were
relative rankings based on a national average, a state
might move from one quintile in one map to an adja-
cent quintile in another map, although this move might
not be statistically significant. Six states shifted down
two quintiles across the two datasets (OH, FL, DC, TX,
DE, and CA), and six states shifted up by two or more
Table 2 Correlations of State-level BRFSS to State-level Prescription Drug Filled
1999 2000 2001 2002 2003
BRFSS Q: “Have you ever been told by a doctor that you have diabetes?”
correlated with diabetes prescriptions filled
0.588a 0.609a 0.625a 0.695a 0.713a
N (50 states plus the District of Columbia) 51 51 51 51 51
BRFSS Diabetes (State-level):
Meanb 5.59% 6.05% 6.45% 6.66% 7.14%
Standard Deviation 0.95% 0.87% 1.24% 1.20% 1.31%
Prescriptions-Filled (State-level):
Mean 3.38% 3.55% 3.76% 3.99% 4.13%
Standard Deviations 0.70% 0.73% 0.74% 0.78% 0.79%
Ratio of Rx/BRFSS rates 0.62 0.60 0.60 0.62 0.59
Prescriptions-Filled (County-level):
Mean 2.22% 2.33% 2.47% 2.62% 2.73%
Standard Deviation 1.34% 1.41% 1.49% 1.59% 1.64%
N (counties) 3,103 3,103 3,103 3,103 3,103
a = Correlation is significant at the 0.01 level (2-tailed)
b = Mean of the state-level rates, not a computed national rate.
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quintiles (ND, NE, IA, MN, WI, and CT). For the first
group, the differences between disease prevalence and
drug treatment could not be attributable to underdiag-
nosis because the individuals reported that they had
been told by a medical professional that they had the
chronic illness. For the second group, while self-
reported prevalence was relatively low in these states, a
fairly large number of prescriptions were filled in these
states. Medications could be overprescribed to residents,
or nonresidents were filling prescriptions in that region
Figure 1 State-Level Percentage of the Adult Population Told by a Doctor They Have Diabetes (BRFSS), 2003. Note 1: Behavioral Risk
Factor Surveillance System is used in the map. Note 2: Interpreted as the percent of the adult population told by a doctor they have diabetes in
2003. Note 3: 50 states and DC reporting. Note 4: Population 18+ is shown.
Figure 2 State-Level Percentage of the Adult Population Who Filled Diabetes Prescriptions, 2003. Note 1: IMS Health Xponent is used in
the map. Note 2: Interpreted as the percent of the adult population who filled prescriptions in 2003. Note 3: 50 states and DC reporting. Note 4:
Population 18+ is shown.
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at a higher rate than in other states; alternatively, these
states may have perfectly acceptable prescription-fill
rates, but other states could be underprescribing.
Further investigation would be necessary to support
either conclusion. The Global Moran’s I for Figure 2 is
0.50, which indicates a relatively low degree of positive
spatial autocorrelation (ie, the spatial pattern is not ran-
dom) (p = 0.001). The prescriptions-filled map contains
the same degree of spatial autocorrelation as the BRFSS
state map (0.50 vs. 0.57).
The advantage county-level prescription data offer is
the ability to inspect intrastate and regional differences
in prescription rates. Figure 3 maps refined rates of
filled diabetes prescriptions at the county level for the
year 2003. We used the same colors and standards of
quintile categories as the BRFSS map to facilitate com-
parisons among the BRFSS state map, the prescriptions-
filled state map, and the prescriptions-filled county map.
The Figure 3 map shows a much more varied distribu-
tion of diabetes prevalence (expressed by fill rates) and a
possible disconnect between prescription fill rates and
geographic estimates of diabetes prevalence from
mapped BRFSS data in Figure 1. When individual
county rates were calculated and mapped, the range of
prescriptions-filled rates expanded to 0% to 17.61% (two
counties were considered outliers: Adams County, ND,
has a diabetes prescription-fill rate of 17.61%, while
Montour County, PA, has a rate of 13.97%. The
remainder of the counties in this top quintile falls
between 3.99% and 10.76%.).
Striking prescription-fill rate differences were found
within the “very high” prevalence states. One reason for
the markedly varied sub-state levels is that county-level
population calculations do not permit urban counties to
overwhelm the rural counties. Another explanation for
the variety was that prescription-fill rates vary dramati-
cally within states and regions. Therefore, using state-
level data alone may be insufficient to appropriately tar-
get areas with high or low prevalence.
Three interesting patterns are noteworthy. First, coun-
ties with relatively low prescriptions-filled rates in states
with overall high rates of prevalence may identify clus-
ters of undermedication. Likewise, counties with rela-
tively high prescriptions-filled rates within states with
relatively low prevalence rates were similarly identified
as sites for further investigation. Finally, adjacent coun-
ties where the rates differ by two or more categories (e.
g., dark brown adjacent to light green) may suggest fun-
damental differences between the two counties in either
the resident population or health care delivery system–
or reflect concentrations of residents crossing county
lines for their prescriptions. In regard to this last pat-
tern, Iowa was an excellent example. While at the state-
level Iowa had a relatively low self-reported prevalence
and “average” rate of prescriptions filled, it showed a
great variety among counties, sometimes even in
Figure 3 County-Level Percentage of the Adult Population Who Filled Diabetes Prescriptions, 2003. Note 1: IMS Health Xponent is used
in the map. Note 2: Interpreted as the percent of the adult population who filled diabetes prescriptions in 2003. Note 3: 50 states and DC
reporting. Note 4: Population 18+ is shown.
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adjacent counties. While the county-level map generated
using prescriptions-filled data matches the general pat-
tern of the state-level BRFSS map, it also displayed
potentially important regional differences as well as sig-
nificant levels of intercounty variation. Planning appro-
priate health care interventions for diabetics would
more likely be improved by using the county-level rather
than the state-level map. Shifting the scale from the
state level to the county level changes the spatial statis-
tic dramatically. The Global Moran’s I for Figure 1 is
0.0947, which indicates an almost total absence of
spatial autocorrelation (ie, the spatial pattern is random)
(p = 0.001).
Heart Disease
We compared coronary heart disease (BRFSS) to the
broader category of heart disease prescriptions filled
(coronary heart disease is a subset of all heart diseases;
to avoid confusion in this article, coronary is set off in
italics). Diseases of the heart are the leading cause of
death in the US, responsible for 29% of deaths in 2001
and 2002 [40]. In 2003, cardiovascular disease was an
underlying cause of death in 37% of all cases and an
underlying or contributing cause of death in 58% of all
deaths [41]. From 1992-2002, 1 in 3 adults was esti-
mated to have cardiovascular disease, roughly 71 million
people [42]. Another study (1999-2000) estimated preva-
lence of cardiovascular diseases to be 34% of the total
population [43]. The estimated prevalence of coronary
heart disease (in 1999-2000) was 7% of the total popula-
tion and 8% for males [44]. Thus, the broad category of
heart disease may be roughly 33% of the population,
while coronary heart disease is estimated in 7% of the
population. But the definitions used to measure these
diseases have changed several times (e.g., International
Classification of Diseases, revisions 6-10), so precise
trend studies are difficult to produce. Additionally,
national prevalence rates are derived from sample-based
surveys such as the NHANES and the BRFSS [45]. Sur-
veys are subject to sampling variability as well as survey
design flaws, respondent classification errors, data pro-
cessing mistakes, and poor coverage of the population.
Specifically, we were concerned about the inability of
survey data to estimate small area disease prevalence,
particularly in rural areas where individuals were not
surveyed.
If cardiovascular disease was eliminated as a cause of
death, life expectancy at birth would increase nearly
seven years [46]. Of all deaths attributed to heart dis-
ease, 17% occurred in people under age 65 and were
considered premature deaths [47]. “Reducing premature
death from heart disease and eliminating disparities will
require preventing, detecting, treating, and controlling
risk factors for heart disease in young and middle-aged
adults” [48]. Ironically, the leading cause of death was
not tracked in every state, in every year via the BRFSS,
which was conducted by each state. Just 24 states admi-
nistered this health question in 2003.
The state-level BRFSS coronary heart disease preva-
lence rates correlate with the state-level IMS Health
heart disease prescription rates between 0.44 to 0.61
(p < .01, Table 3.). These correlations were based on
data from 20 to 24 states, and correlations based on
samples of fewer than 30 may be unstable. The BRFSS
mean state-level adult prevalence rate for coronary heart
disease is roughly 4.4%; the state-level adult heart
Table 3 Correlations of State-level BRFSS to State-level Rx
1999 2000 2001 2002 2003
BRFSS Q: “Have you ever been told by a doctor that you have coronary heart disease?“ compared to
heart disease prescriptions filled
0.438a – 0.662a – 0.613a
N (states) 21 14 20 7 24
BRFSS Heart Disease (State-level):
Meanb 4.27% – 4.47% – 4.48%
Standard Deviation 0.90% – 1.08% – 1.39%
Prescriptions-Filled (State-level):
Mean 15.19% 16.04% 16.99% 18.02% 18.74%
Standard Deviations 3.44% 3.57% 3.64% 3.83% 3.96%
Ratio of Rx/BRFSS rates 1.60 – 1.57 – 2.25
Prescriptions-Filled (County-level):
Mean 9.41% 10.01% 10.60% 11.28% 11.85%
Standard Deviation 5.92% 6.33% 6.64% 7.05% 7.32%
N (counties) 3,103 3,103 3,103 3,103 3,103
Note: Correlations with populations of less than 30 are unstable and should be viewed with caution.
a = Correlation is significant at the 0.01 level (2-tailed)
b = Caution: Mean of the state-level rates, not a calculated national rate
– Data unavailable
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disease prescriptions-filled rate ranged from 15.2%
(1999) to 18.7% (2003). When the prescriptions were
reported at the county level, the average rate was 9.4%
(1999) to 11.9% (2003). Nearly 1 in 6 adults fills orders
for heart disease prescription drugs, half of estimated
prevalence rates. The ratio of the prescriptions-filled
rates to BRFSS prevalence rates range from a low of 1.6
to 2.3.
The BRFSS self-reported prevalence ranged from
2.06% to 8.72% (Figure 4). The map contains five states
in each category except for the top 20% category. This
map shows four central southern states ranked “very
high” in coronary heart disease prevalence rates (5.3%+);
the remainder of the South ranks as an area of “high” or
“average” prevalence (4.2% - 5.3%). The majority of
states in the Midwest and West did not report this
question, although half of the eight “low” and “very low”
prevalence states were in the Midwest and West. The
BRFSS mapped state-level data suggests coronary heart
disease prevalence rates were divided into high-preva-
lence Southeast and low-prevalence Midwest and West
zones, with a cluster of very high-prevalence states that
roughly follow the Appalachian mountain region.
In comparison, the IMS Health state-level prescription
data map (Figure 5) filled in the missing states, complet-
ing the health picture of the Midwest and West. It also
reinforced the same cluster of high rates in the South-
east, while low rates were clustered in the Midwest and
West. Arkansas reported in the “very high” quintile of
coronary heart disease, but was ranked “average” for
heart disease prescriptions filled, perhaps suggesting
residents were undertreated via drugs for heart disease.
Five states shifted by two or more categories. Since
these categories are based on relative (state-to-state)
measures, it was not possible to link actual need for pre-
scriptions to prescription rates in each state. Rather, it
suggested which states warranted further investigation.
The Global Moran’s I for Figure 5 is 0.56 (p = 0.001),
which indicates a low level of positive spatial
autocorrelation.
The Figure 6 map shows a much more varied distribu-
tion of heart disease prevalence (expressed by fill rates)
along with a possible disconnect between prescription
fill rates and the geographic estimates of coronary heart
disease prevalence from mapped BRFSS data in Figure
4. The range of rates was expanded to 0% to 70.8%
(although two counties in which the rate was 50% or
more were interpreted as regional distribution centers.
The reported heart disease prescription-fill rate is
70.81% for Adams County, ND, and 56.16% for Mon-
tour County, PA. Without further investigation, we
assume these to be prescription distribution centers.
The remainder of the counties falls under 50%.).
Striking intercounty differences in prescription fill
rates were found within the “very high” prevalence states
as well as the “very low” prevalence states. Again, the
Figure 4 State-Level Percentage of the Adult Population Told by a Doctor They Have Coronary Heart Disease (BRFSS), 2003. Note 1:
Behavioral Risk Factor Surveillance System is used in the map. Note 2: Interpreted as the percent of the adult population told by a doctor they
have coronary heart disease in 2003. Note 3: 22 states and DC reporting. Note 4: Population 18+ is shown.
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most informative patterns would be low prescription-
fill-rate counties in states with overall high prevalence
rates, high prescription-fill-rate counties in states with
overall low prevalence rates, and “very high” or “high”
prescription-fill-rate counties adjacent to “low” or “very
low” prescription-fill-rate counties. Shifting scale from
the state to county level changes the spatial statistic dra-
matically. The Global Moran’s I for Figure 6 is 0.08 (p =
0.001), which indicates a near absence of spatial
autocorrelation.
Figure 5 State-Level Percentage of the Adult Population Who Filled Heart Disease Prescriptions, 2003. Note 1: IMS Health Xponent is
used in the map. Note 2: Interpreted as the percent of the adult population who filled heart disease prescriptions in 2003. Note 3: 50 states and
DC reporting. Note 4: Population 18+ is shown.
Figure 6 County-Level Percentage of the Adult Population Who Filled Heart Disease Prescriptions, 2003. Note 1: IMS Health Xponent is
used in the map. Note 2: Interpreted as the percent of the adult population who filled heart disease prescriptions in 2003. Note 3: 50 states and
DC reporting. Note 4: Population 18+ is shown.
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Stroke
Similar to coronary heart disease versus general heart dis-
ease, stroke medications are used to treat a fraction of
hypertension cases. Thus, we would expect that the pre-
scription rates would be lower than the broader self-
reported rates of hypertension. Correlations for state-level
BRFSS self-reported hypertension prevalence rates to
state-level IMS health stroke prescription rates ranged
from 0.41 to 0.62 (p < .01, Table 4.) The BRFSS mean
state-level adult hypertension prevalence rate ranged from
24.3% to 25.6%, while the state-level adult stroke prescrip-
tions-filled rate ranged from 3.4% to 4.6%. When the pre-
scription rates for counties were calculated, the average
rate dropped from 1.9% to 2.7%. The ratio of the prescrip-
tions-filled rates to the BRFSS prevalence rates ranged
from 0.15 to 0.19, remaining relatively stable across time.
Figure 7 displays mapped BRFSS data. All 50 states
and the District of Columbia administered this question
in 2003. The map contains 10 states in each category
except for the dark green (bottom 20%) category with
11. The state-level BRFSS self-reported prevalence ran-
ged from 19% to 34%. This map shows 10 states ranked
“very high” (29-34%) in self-reported hypertension pre-
valence rates. The remainder of the South and Central
regions ranked as areas of “high” or “average” prevalence
(24-29%). The majority of Midwest and Western states
ranked as “very low” (19-23%) and “low” (23%-24%).
The BRFSS mapped state-level data show hypertension
prevalence rates were divided into high-prevalence
Southeast and low-prevalence Midwest and West
regions, with a cluster of very high-prevalence states
roughly following the Appalachian region. The Global
Moran’s I for Figure 7 is 0.54, indicating low, positive
spatial autocorrelation (p = 0.001).
In comparison, the IMS Health state-level prescrip-
tion map (Figure 8) showed stroke prescriptions filled
shifting to the Midwest, while the Southeast had a less
distinct pattern of very high and high rates of stroke
prescriptions filled. Six states shifted down (from self-
reported stroke to prescriptions filled). Residents of
these states may be at risk for undertreatment by
drugs for hypertension. This methodology cannot
answer the public health question of health care
access, but the inconsistency between the two maps is
suggestive.
Shifts in the opposite direction were also seen in
eight states. Perhaps more residents in these states
filled hypertension prescriptions for treatment of their
chronic disease compared to residents in other states.
Likewise, the proportion with hypertension treated
with prescriptions to those with diagnosed hyperten-
sion may be unusually high. We cannot ascertain the
cause of this shift using current data. The Global Mor-
an’s I for Figure 8 is 0.37, indicating little spatial auto-
correlation (p = 0.001).
Figure 9 shows a varied county-level distribution of
risk for stroke prevalence (expressed by prescription fill
rates), ranging from 0% to 16% (two counties with rates
above 15.8% were interpreted as regional distribution
centers. The reported stroke prescription fill rate is
23.77% for Montour County, PA, and 19.01% for Adams
County, ND. The remainder of the top quintile counties
falls within the range of 4.12% and 15.75%).
Striking intercounty differences in prescription fill
rates were found within the “very high” prevalence
states, as well as in the “very low” prevalence states. The
most informative patterns would be low prescription-
fill-rate counties in states with overall high prevalence
Table 4 Correlations of State-level BRFSS to State-level Rx
1999 2000 2001 2002 2003
BRFSS Q: “Have you ever been told by a doctor that you have hypertension?” compared to Stroke
prescriptions filled
0.406a – 0.499a – 0.622a
N (50 states plus the District of Columbia) 51 – 51 – 51
BRFSS Hypertension (State-Level): – –
Meanb 24.32% – 25.69% – 25.56%
Standard Deviation 3.22% – 2.76% – 3.34%
Prescriptions-Filled (State-level):
Mean 3.44% 3.61% 3.91% 4.29% 4.64%
Standard Deviations 0.69% 0.73% 0.77% 0.87% 0.96%
Ratio of Rx/BRFSS rates 0.15 – 0.16 – 0.19
Prescriptions-Filled (County-level):
Mean 1.91% 2.00% 2.18% 2.41% 2.67%
Standard Deviation 1.45% 1.53% 1.66% 1.82% 1.99%
N (counties) 3,103 3,103 3,103 3,103 3,103
a = Correlation is significant at the 0.01 level (2-tailed)
b = Mean of the state-level rates, not a calculated national rate
– Data unavailable
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rates, high prescription-fill rate counties in states with
overall low prevalence rates, and “very high” or “high”
prescription-fill rate counties adjacent to “low” or “very
low” prescription-fill rate counties. The Global Moran’s
I for Figure 9 is 0.03, indicating an absence of spatial
autocorrelation (p = 0.001).
Discussion
Based on the overall correlation results, we argue that
prescription rates have the potential to be a useful and
informative proxy for disease-specific diagnosed preva-
lence at both the state and county levels. Although we
did not begin with a priori correlation goals, the results
Figure 7 State-Level Percentage of the Adult Population Told by a Doctor They Have Hypertension (BRFSS), 2003. Note 1: Behavioral
Risk Factor Surveillance System is used in the map. Note 2: Interpreted as the percent of the adult population told by a doctor they have
hypertension in 2003. Note 3: 50 states and DC reporting. Note 4: Population 18+ is shown.
Figure 8 State-Level Percentage of the Adult Population Who Filled Stroke Prescriptions, 2003. Note 1: IMS Health Xponent is used in
the map. Note 2: Interpreted as the percent of the adult population who filled stroke prescriptions in 2003. Note 3: 50 states and DC reporting.
Note 4: Population 18+ is shown.
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are sufficiently encouraging to warrant further investiga-
tion. With refinement of the methodology (see Future
Directions below), we envision a powerful tool for health
care planners, especially in rural areas. We did have an
a priori expectation to see spatial autocorrelation (ie,
geographic clustering) in rural areas because of the
widespread belief that rural areas are at a disadvantage
with respect to access to health care. However, this was
clearly not the result, suggesting greater access to pre-
scription drugs in rural areas than was originally
thought. Finding no spatial autocorrelation at the
national level is informative. But equally useful and not
yet analyzed is spatial autocorrelation within states or
regions that could prove enlightening to state health
officials. Also unexamined are the geographic changes
over time at the state, regional, and national levels. This
methodology shows promise, especially for those indivi-
duals who are responsible for addressing the allocation
of health resources and reducing health inequalities.
This methodology’s greatest potential is in providing a
measure of diagnosed prevalence for rural counties,
areas not sufficiently sampled in national surveys.
Limitations
The progression from illness to prescription treatment is
a series of steps - at any point, an individual can aban-
don the progression. Briefly, these steps include: (a) the
patient’s recognition of a medical need, (b) the patient
decides to seek medical care, (c) the patient has access
to medical care (overcoming physical, temporal, finan-
cial, and social constraints), (d) the patient is diagnosed,
(e) the appropriate treatment includes a prescription
drug, (f) the patient has access to prescription drugs
(overcoming physical, temporal, financial, and social
constraints), and (g) the patient fills the prescription and
refills it regularly, having taken it as prescribed. How-
ever, to have been diagnosed, a patient must meet the
first five of these steps. Thus, using prescription drug
data to estimate prevalence is risky only in that the
patient must have access to prescriptions and take them
as prescribed, refilling regularly (not sharing or skipping
doses).
The single biggest limitation to this methodology is
that data regarding prescription drugs filled is limited to
diagnosed and treated disease. Several studies have sup-
plemented the diagnosed diabetes data in NHANES
(“... have you even been told by a doctor or health pro-
fessional that you have diabetes or sugar diabetes?”)
with blood samples drawn from the respondents (a fast-
ing plasma glucose level of >126 mg/dL was coded as
having diabetes). In a study of 1992-2002 NHANES
data, Cowie et al found that some 30% of the nation’s
crude prevalence of total diabetes was undiagnosed [49],
based on the additional blood tests. This finding was
echoed in a study using 2003-2006 NHANES data by
Danaei et al, [50] who found that 32% of total national
diabetes is undiagnosed. A slightly higher percentage,
about 40%, was found by Cowie et al using 2005-2006
Figure 9 County-Level Percentage of the Adult Population Who Filled Stroke Prescriptions, 2003. Note 1: IMS Health Xponent is used in
the map. Note 2: Interpreted as the percent of the adult population who filled stroke prescriptions in 2003. Note 3: 50 states and DC reporting.
Note 4: Population 18+ is shown.
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NHANES data and blood tests [51]. As a methodologi-
cal extension, Danaei et al applied their NHANES analy-
sis methodology to state-level BRFSS data (2003-2007).
They were able to report undiagnosed diabetes at the
state level by age, sex, race, and insurance status. While
this is an advance in terms of smaller geography (state
vs. national), the BRFSS data are limited to state or
large metropolitan areas. Conversely, since the prescrip-
tion dataset does not contain demographic data, a
further extension of Danaei et al’s methodology is not
feasible for county-level analysis. Researchers have also
used the family history data in NHANES to estimate
undiagnosed and pre-diabetes; however, this methodol-
ogy is limited to national results [52-55].
The BRFSS survey data also have their own limitations
in that individuals must have a landline telephone to
participate; must be randomly chosen to participate;
must answer the surveyor’s call; must agree to partici-
pate if they do answer the phone; and must respond
accurately to health status questions (ie, no faulty mem-
ory, avoidance of questions, etc.).
Measuring prescription-fill rates to use as a proxy
measure of the prevalence of specific chronic illnesses is
a crude methodology, fraught with possible disconnects,
as the list above suggests. Nonetheless, we have accom-
plished an important validation exercise. Beyond what is
listed above, we are aware of the coverage limitations of
this prescription dataset, specifically the selection of the
basket of drugs used to treat each disease. More specifi-
cally, we worked with IMS Health to create a basket of
drugs that represents the best practices for the time per-
iod studied. IMS Health is the leading firm in the collec-
tion, analysis, and dissemination of prescription drug
data in the US. They are aware of prescribing practices
and trends in prescription drugs. Because the match
between drug and illness is as much knowledge of what
is occurring in the industry as it is the current medical
guidelines, at the onset of the project, and very specifi-
cally, we chose IMS Health to select drug classes. Based
on the objectives for the research and the specific dis-
ease states it planned to address, IMS recommended
specific categories of drugs to include in the data
extracted and provided. Though treatment practices
change, most evidence indicates that they change slowly
and should not have a dramatic effect on what we have
presented here. Finally, when flows of individual drugs
are examined, altering one or two in the calculations
would have no effect on the overall conclusion of this
manuscript, which is a new and potentially valuable,
albeit imperfect, methodology to measure population
health.
These issues need to be addressed in future refine-
ment of this methodology. Indeed, many drugs are used
to prevent or slow the onset of chronic illness. One
future solution might be to link prescription-filled data
with a survey of physicians’ prescribing practices (e.g., of
your patients for whom you prescribe heart disease
medications, what percentage are preventative versus
treatment for existing disease?).
The BRFSS and the IMS Health data measure slightly
different things. Limitations of the BRFSS measure
include recall bias, as well as lack of data on whether
the respondent still had the disease or whether they
were treating it with medications. The IMS data mea-
sure those who are treating their disease with medica-
tion due to disease progression, in conjunction with the
ability to pay for care and treatment.
The correlations in 1999 were consistently lower than
in later years. The base population in 1999 was a popu-
lation estimate–as opposed to a census count, which
occurred in 2000 –which may partially account for the
differing magnitude between 1999 and subsequent years.
The percentage change in population between 1999 and
2000 was as high as 12% in some counties, whereas in
year-to-year comparisons (2000-2003), the state popula-
tion differed by no more than 4%.
The national estimates from surveys were higher than
prescriptions-filled rates due to incremental losses in the
base population. There are several reasons prescriptions
might not be counted. First, there are people outside the
medical system, whether they excluded themselves prior
to diagnosis or at the point of the doctor’s office (those
who were not diagnosed or not treated) or possibly at
the point of the pharmacy (individuals who did not fill
their prescriptions). A second category of exclusion was
the distribution of drugs used in a clinical setting, such
as a hospital (e.g., emergency room or surgery), clinic
(e.g., chemotherapy and radiation) or the doctor’s office
(e.g., samples), although this would account for only a
small percentage of chronic disease drugs, as opposed to
other drug categories. The third category of exclusion
from the prescriptions-filled dataset is nonparticipation
in the prescription tracking program by the pharmacy
or by the patient (e.g., mail-order purchases or pur-
chases made outside the US); however, IMS Health
accounts for this exclusion through estimation of the
total prescriptions for the retail channel.
Additionally, all prescriptions were not filled in the
county of patients’ residence, although no test has yet
been made of what percentage of prescriptions were
filled outside of the county of residence [56]. Finally,
there is the issue of off-label usage; we assume people
who fill chronic disease prescriptions have that disease,
as off-label usage is not perceived to be an issue with
these particular classes of drugs.
Variations between self-reported prevalence rates of
BRFSS and those currently in drug therapy for those
diseases remain unaccounted for and are likely due to
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the BRFSS method of oversampling densely populated
metropolitan areas (with the IMS data capturing all pre-
scriptions) and variation between the rate of self-
reported prevalence versus drug therapies. In other stu-
dies, the differences between treatment patterns [57],
prescribing practices, and dispensing practices [58] have
all been noted in state-level studies [59]. Finally, this
methodology begs further exploration and refinement.
We paired drug classes with appropriate BRFSS ques-
tions, but those choices can be challenged and should
be tested.
Conclusions
We tested the IMS database as a proxy for BRFSS pre-
valence, using diabetes, heart disease, and stroke as test
chronic health conditions. Validated, this methodology
can provide an efficient and timely county-level chronic
disease surveillance system. Ultimately, the data can be
used to detail the spatial characteristics of diabetes,
heart disease, and stroke while investigating correlations
among ecological, socioeconomic, and environmental
conditions as a means of further exploring the social
determinants of these chronic illnesses. Our spatial ana-
lyses indicate vast county-level variation in each of these
prescription drug classes–variations that will need to be
taken into account in future research as well as in the
distribution of health-related resources.
Future Directions
This area of inquiry affords many opportunities and
issues for further exploration. To improve the accuracy
of our estimates, (ie, county-level prevalence rates), the
“cohort change ratio” technique could be employed
rather than using US Census Bureau estimates [60,61].
Also, additional comparisons with other national health
surveys, comparisons against regional- or county-level
prevalence (if such data exist), and with a health provi-
der’s dataset (e.g., Blue Cross & Blue Shield or Express
Scripts) should be explored. Finally, future researchers
should seek a better calibration and correlation between
drug classes and chronic illness, especially as they relate
to heart disease and stroke. This could be informed via
a survey of physician prescribing habits as well as disag-
gregating drug classes to test for correlations to specific
illness, although this would not control for how treat-
ment therapies change over time, nor the geographic lag
that may exist for treatment regimen change.
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